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ABSTRACT
BACKGROUND: Patients with various structural brain lesions often suffer from seizures. Refractory epi-
lepsy is the most common in brain tumors, vascular malformations, and sequel of cerebral infections, infarcts
or trauma. OBJECTIVE: To evaluate the efficacy and safety of new AEDs in patients with medically refrac-
tory seizures associated with structural brain lesions. MATERIAL AND METHODS: Twenty-six (26) pa-
tients (8 M; 18 F), aged 48.4± 7.6 years, with simple (65%) or complex partial (35%) seizures associated with
cerebral tumors (12 p) and non-neoplastic brain lesions (14 p) were included in the study. Diagnosis was based
on the criteria of ILAE. Patients were treated with OXC (10 cases), LTG (9 cases), and LEV (7 cases) for at
least six months. Efficacy and tolerability were assessed on the basis of changes in seizure frequency and re-
porting the drugs side effects. Structural neuroimaging, EEG, and clinical follow-up were performed before
and after AEDs addition. RESULTS: Eighteen (18) patients (72%) were seizure-free after six to twenty-four
months treatment period and 8 (28%) experienced some rare partial seizures but no more generalized at-
tacks. Side effect of mild somnolence was observed in 4 patients treated with LTG during the first 3 weeks of
the treatment, of transient dizziness in 3 patients under OXC, and transient fatigue in 2 patients treated with
LEV. CONCLUSION: In accordance with our own findings and literature review, we suggest that new AEDs
due to their efficacy and good safety profile might be useful for the epilepsy control in patients with medically
refractory seizures associated with structural brain lesions.
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INTRODUCTION
Epilepsy is the most common neurological disorder, esti-
mated to affect 50 million people worldwide (12). Patients
with various structural brain lesions (tumors, vascular mal-
formations, and sequel of cerebral infections, infarcts or
trauma) often suffer from seizures (1,2,4,5,7,13). Refractory
epilepsy is common in these cases and a role for multidrug
resistance proteins has been suggested (4,9,10,12).
The most frequently prescribed "first-generation" anti-epi-
leptic drugs (AEDs) interact with other medications, com-
plicating their dosing and effectiveness (2,9,12). Many sec-
ond-generation AEDs are not metabolized in the liver and
have fewer drug interactions (5,6,8,11). This must be con-
sidered when designing a treatment strategy for refractory
epilepsy and evaluating efficacy, tolerability, and toxicity
(1,2,8,12). The introduction of new AEDs in the last twenty
years has provided greater choice for patients and physi-
cians (3,6,8,9,10,11,13). Accordingly we decided to evalu-
ate the efficacy and safety of Oxcarbazepine (OXC),
Lamotrigine (LTG), and Levetiracetam (LEV) in patients
with medically refractory partial and secondary generalized
seizures associated with different structural brain lesions.
MATERIAL AND METHODS
Twenty-six patients (26) (8 M; 18 F), aged 48.4 ±7.6 years,
with uncontrolled seizures associated with cerebral tumors
(12 p) and non-neoplastic brain lesions (14 p: benign
arachnoid cysts - 4 p, brain infarction with sequel - 4 p, ce-
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Fig.1. Distribution of patients according to the type of
brain lesion.
rebral angiomas - 3 p, and cerebral trauma with sequel - 3 p)
were included in the study (Fig. 1). Patients presented with
simple (65%) or complex partial (35%) seizures with sec-
ondary generalization. Diagnosis was based on the criteria
of International League Against Epilepsy (ILAE). Ten pa-
tients were treated with OXC (1200-1800 mg/daily), nine
with LTG (200-400 mg/daily), and seven with LEV
(2000-3000 mg/daily) for at least six months (Fig. 2).
Efficacy was assessed on the basis of changes in seizure
frequency and tolerability with reporting the adverse effects
related to the drug. All patients underwent computed to-
mography (CT) or magnetic resonance imaging (MRI),
electroencephalography (EEG) monitoring, and clinical as-
sessment before and every six months after AEDs addition.
RESULTS
Efficacy
All patients exhibited clinical improvement. Eighteen (18)
patients (72%) were seizure-free after 6 to 24 months treat-
ment period and 8 (28%) experienced some rare partial sei-
zures but no more generalized attacks.
Adverse Events
Side effect of mild somnolence was observed in 4 patients
treated with LTG during the first three weeks of the treat-
ment, of transient dizziness in 3 patients under OXC, and
transient fatigue in 2 patients treated with LEV.
DISCUSSION
According to the Consensus proposal by the ad hoc Task
Force of the ILAE Commission on Therapeutic Strategies,
about 40% of patients have structural/metabolic etiology of
epilepsy (1). Most of them are considered drug resistant,
because the application of 2 AEDs as a mono- or combined
therapy is not successful (2,5,7,12). Although the signifi-
cant success achieved in the treatment of epilepsy over the
past decades, about one third of patients with epilepsy have
bad seizures control with current AEDs (5,10,12,13). Clini-
cal evidences exist that even in patients with efficacious
pharmacotherapy; the underlying mechanisms of
epileptogenesis are not successfully affected (4,7,9).
In relation to these data our study group consisted of pa-
tients with acquired or congenital structural brain lesions.
All patients had intractable seizures requiring add-on ther-
apy with new AEDs. The analysis of our results revealed
that use of OXC, LTG, and LEV reduced significantly the
frequency of seizures in all patients (3,6,8,10,11). These
findings are in accordance with recent studies confirming
the high efficacy of novel anticonvulsants (5,6,10,12). In
addition, the percentage of side effects observed in our
study groups (respectively 30.0%, 44.4%, and 28.5%) is
consistent with literature data (4,6,9,11). Furthermore, the
most common side effects we found in our patients treated
with OXC (mild transient dizziness), LTG (transient som-
nolence), and LEV (fatigue) are similar to those described
in the available literature (1,3,6,8,11).
In summary, despite the heterogeneous and limited group
of patients included in this study, our observations revealed
data that proved the use of new AEDs in successful manag-
ing of refractory epilepsy.
CONCLUSION
In accordance with our own findings and literature review,
we suggest that new AEDs such as LTG, OXC, and LEV
demonstrate high efficacy and good safety profile. Obvi-
ously, this novel pharmacotherapy benefits the epilepsy
control and improves the quality of life of patients with
medically refractory seizures associated with structural
brain lesions.
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